Bamlanivimab + Etesevimab 350/700 mg safely reduces viral load

Photo credit: andresr

Below is a summary of “Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Study for Mild to Moderate COVID-19,” published in the September 2024 issue of Infectious diseases by Patel et al.

The monoclonal antibody therapies bamlanivimab (BAM) + etesevimab (ETE) received emergency use authorization (EUA) from the U.S. Food and Drug Administration (February 9, 2021) for the treatment of mild to moderate COVID-19.

Researchers conducted a retrospective study to evaluate the efficacy and safety of the 350/700 mg dosage of BAM and ETE for the treatment of mild to moderate COVID-19.

They conducted a Phase 3 BLAZE-1 study (J2X-MC-PYAB) between June 17, 2020, and April 9, 2021. The study enrolled patients with mild to moderate COVID-19 diagnosed within 3 days of SARS-CoV-2 infection. A total of 354 patients were randomized (2:3) to receive either placebo (N = 141) or 350/700 mg BAM + ETE (N = 213) over a period of approximately 8 minutes. In addition, the proportion of patients with persistently high SARS-CoV-2 viral load (PHVL) (log viral load > 5.27) 7 days after infusion was determined.

The results showed that patients with a mean age of 53 years, 49.7% female and 82.7% white, 10.8% (95% CI: 6.6, 15.0; PP

They concluded that treatment with BAM + ETE reduced the proportion of patients with PHVL and resulted in a more significant reduction in viral load than placebo. The safety profile of BAM + ETE was favorable, and infusions lasting over 8 minutes did not result in an increased incidence of adverse events compared to higher doses administered over 30-60 minutes.

Source: link.springer.com/article/10.1007/s40121-024-01031-z